Safe administration of subsequent mRNA COVID-19 vaccine doses following a possible allergic reaction to the first dose.

Roth, M S; Chantraine, S; Morales Mateluna, C A; Hartmann, K; Berger, C T

Roth, M S; Chantraine, S; Morales Mateluna, C A; Hartmann, K; Berger, C T.

Roth MS; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
Chantraine S; Division of Allergy, University Children's Hospital of Basel, Basel, Switzerland.
Morales Mateluna CA; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
Hartmann K; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.
Berger CT; Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland.

J Eur Acad Dermatol Venereol ; 36(11): e880-e883, 2022 11.

Article in English | MEDLINE | ID: covidwho-2278851

Subject(s)

COVID-19 Vaccines; COVID-19; Hypersensitivity; COVID-19/prevention & control; COVID-19 Vaccines/adverse effects; Humans; RNA, Messenger

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 / Hypersensitivity Topics: Vaccines Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2022 Document Type: Article Affiliation country: Jdv.18387

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google